There has been a recent renaissance in the interest in radiopharmaceuticals used for diagnostic and therapeutic applications, as well as their combined use (theranostics). A recent Canadian partnership between Admare Bioinnovations and the Centre for Probe Development and Commercialization (CPDC) aims to take advantage of the country’s expertise in the field and leverage promising radiopharmaceutical innovations into potential commercial opportunities.
PERTH, Australia – Melbourne-based Telix Pharmaceuticals Ltd. has linked up with Hong Kong-listed China Grand Pharmaceutical and Healthcare Holdings Ltd. (CGP) in a licensing and commercial deal worth AU$400 million (US$285 million) plus sales royalties.
PERTH, Australia – Melbourne-based Telix Pharmaceuticals Ltd. has submitted its first new drug application to the FDA for TLX591-CDx, a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) for imaging prostate cancer using positron emission tomography (PET).
PERTH, Australia – Melbourne-based Telix Pharmaceuticals Ltd. has submitted its first new drug application to the FDA for TLX591-CDx, a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) for imaging prostate cancer using positron emission tomography (PET).
Reflexion Medical Inc. appears to be on a roll. A little more than a month after unveiling a tie up with Merck & Co. Inc., it now has reported a collaboration with Telix Pharmaceuticals Ltd., a radiopharmaceutical company developing molecularly targeted radiation products.
PERTH, Australia – Telix Pharmaceuticals Ltd. raised AU$40 million as it prepares regulatory packages and commercial strategies in Europe, the U.S. and Australia.
